Montelucaste Accord (Montelukast Sodium)

Montelukast, the active ingredient in Montelucaste Accord, is a leukotriene receptor antagonist presented as an oral tablet for oral use. It is used to manage asthma, allergic rhinitis and exercise‑induced bronchoconstriction in patients requiring anti‑asthmatic therapy.

GNH USA supplies Montelucaste Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Montelucaste Accord is a leukotriene receptor antagonist indicated for several respiratory conditions: - Asthma: improves control of chronic airway inflammation and reduces frequency of wheezing episodes. - Allergic rhinitis: alleviates nasal congestion, sneezing and itching caused by seasonal allergens. - Exercise‑induced bronchoconstriction: prevents narrowing of airways triggered by physical activity.

Montelucaste Accord may be associated with a range of adverse reactions.

Common Side Effects: - Headache: mild to moderate intensity. - Upper respiratory tract infection: symptoms of cough or sore throat. - Abdominal pain: occasional discomfort or cramping. - Dyspepsia: indigestion or heartburn. - Cough: non‑productive cough episodes. - Fatigue: feeling unusually tired.

Serious or Rare Side Effects: - Mood changes: depression, anxiety, or suicidal thoughts. - Allergic reactions: rash, urticaria, or angioedema. - Hepatotoxicity: elevated liver enzymes or hepatitis. - Stevens‑Johnson syndrome: severe skin blistering. - Anaphylaxis: rapid onset of breathing difficulty and hypotension.

Before prescribing Montelucaste Accord, consider the following safety measures: - Pregnancy: consult a healthcare professional; safety data are limited. - Breastfeeding: assess risk versus benefit; drug may pass into milk. - Hepatic impairment: use with caution; monitor liver function. - Neuropsychiatric events: observe for mood changes or suicidal ideation. - Drug interactions: review concomitant medications for potential CYP450 effects. - Store at ambient temperature: keep below 25 °C, retain original packaging, protect from moisture.

Montelucaste Accord can interact with several medicines; monitoring is advised.

Major Interactions (Avoid): - Phenobarbital: may reduce montelukast plasma concentrations. - Rifampin: induces metabolism, potentially lowering efficacy.

Moderate Interactions (Monitor Closely): - Antidepressants (e.g., fluoxetine): possible additive neuropsychiatric effects. - Antihistamines: may increase sedation. - Warfarin: monitor INR as occasional alterations reported. - St. John's wort: may decrease drug exposure. - Erythromycin: potential increase in montelukast levels.